RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Rosuvastatin Reduces Primary Cardiovascular Events in Apparently Healthy Individuals with Elevated C-Reactive Protein Levels
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 8
IS 8
SP 12
OP 13
DO 10.1177/155989770900800803
UL http://mdc.sagepub.com/content/8/8/12.abstract
AB This large prospective study is the first to show that statin therapy can prevent cardiovascular (CV) events among individuals who do not have elevated lipid levels. The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin [JUPITER; NCT00239681] trial demonstrated that rosuvastatin 20 mg significantly reduced the rate of primary CV events in an apparently healthy population that had normal low-density lipoprotein levels but elevated high-sensitivity C-reactive protein levels.